Genitourinary Cancer
News
FDA approves first agent for PSMA-PET imaging in prostate cancer
The diagnostic agent Gallium 68 PSMA-11 has been approved for institutional use only.
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
Article
Using telehealth to deliver palliative care to cancer patients
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.
News
One-month delay in cancer treatment linked to increase in mortality
The risk of death varied by treatment type.
News
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
PET guidance for radiation therapy improves prostate cancer outcomes
Using PET as well as conventional imaging to guide postprostatectomy radiation therapy reduces the risk of treatment failure.
Conference Coverage
Single and multifraction SBRT found comparable for lung metastases
A single-fraction regimen and a four-fraction regimen netted essentially the same toxicity and oncologic outcomes at 1 year of follow-up.
News
‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients
The NCI-MATCH trial has led to new clinical trial benchmarks, according to the study chair.
Conference Coverage
Lower BP and better tumor control with drug combo?
News
Novel assay may better detect urothelial carcinoma
The UroCAD assay proved more sensitive than urine cytology.
